BRIEF REPORT



A Case Series of Children With 2019 Novel Coronavirus Infection: Clinical and Epidemiological Features

Cai Jiehao,^{1,a} Xu Jin,^{2,a} Lin Daojiong,^{3,a} Yang Zhi,⁴ Xu Lei,⁵ Qu Zhenghai,⁵ Zhang Yuehua,⁵ Zhang Hua,⁷ Jia Ran,² Liu Pengcheng,² Wang Xiangshi,¹ Ge Yanling,¹ Xia Aimei,¹ Tian He,¹ Chang Hailing,¹ Wang Chuning,¹ Li Jingjing,¹ Wang Jianshe,¹ and Zeng Mei¹

¹Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China, ²Divison of Virology, Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China, ³Department of Infectious Diseases, Hainan Women and Children's Medical Center, Shanghai, China, ⁴Department of Infectious Diseases, Anhui Provincial Children's Hospital, Shanghai, China, ⁵Children's Medical Center, The Affiliated Hospital of Qingdao University, Shanghai, China, ⁶Department of Pediatric Infectious Diseases, Haikou People's Hospital, Haikou, Hainan, China, and ⁷Department of Pediatrics, Sanya Central Hospital, Shanghai, China

(See the Editorial Commentary by Fuk-Woo Chan et al, on pages 1552-3.)

We first described the 2019 novel coronavirus infection in 10 children occurring in areas other than Wuhan. The coronavirus diseases in children are usually mild and epidemiological exposure is a key clue to recognize pediatric case. Prolonged virus shedding is observed in respiratory tract and feces at the convalescent stage.

Keyword. 2019 novel coronavirus; coronavirus diseases; children.

A novel coronavirus (2019-nCoV) was identified as the causative agent associated with a cluster of cases of pneumonia detected in Wuhan City by Chinese authorities on 7 January [1]. Since the discovery of 2019-nCoV, the virus has been diagnosed quickly [2, 3]. With the number of people confirmed with 2019nCoV rising rapidly in Wuhan and increasing outside of Wuhan and China, the World Health Organization declared that the outbreak of 2019-nCoV constitutes a Public Health Emergency of International Concern on 30 January 2020 [4]. By 11 February 2020, 44 672 confirmed cases were reported in China with 8255 (18.5%) severe cases and 1023 (2.3%) deaths, and 395 confirmed cases with 1 death were reported in 24 countries outside of China [5, 6]. Thus far, the notifiable cases were mostly among adults, with pediatric cases rarely reported [7, 8]. The clinical profiles of 2019-nCoV infection in children is unknown. Herein we reported the clinical and epidemiological features in children with coronavirus diseases (COVID) in China.

METHOD

Between 19 January and 3 February, 2020, a total of 10 children with confirmed 2019-nCoV infection were admitted to the Children's Hospital in Shanghai, Hainan, Hefei in Anhui province, and Qingdao in Shandong province. According to China Centers for Disease Control and Prevention (CDC) protocol for detection of 2019-nCoV, a duplex 1-step real-time reverse transcription polymerase chain reaction was performed to confirm 2019-nCoV infection at the local CDC reference laboratory. If respiratory samples obtained from patients were successfully tested positive by both open reading frame 1ab gene and nucleocapsid protein gene, the specimens were considered as positive and the case was considered to be laboratory-confirmed. A cycle threshold value <35 was defined as a positive test. All pediatric cases were hospitalized for the screening of 2019nCoV infection when they were considered as suspected cases based on the following 2 criteria: having an epidemiological link to adult cases or an exposure to Wuhan or other epidemic areas in Hubei province and presenting with acute fever and or respiratory symptoms. All patients were admitted to the isolation ward within 2 days after illness onset, and nasopharyngeal and throat swabs were collected immediately for the detection of 2019-nCoV. At the meantime, influenza virus A and B were routinely tested on respiratory swab by colloidal gold assay for all patients.

RESULTS

The detailed information on patients was shown in Table 1. Seven (70%) children were local residents, 2 (20%) were from Wuhan, and 1 (10%) was from Xiaogan (an endemic area 50 kilometers far away from Wuhan). Eight (80%) children had direct contact with adult patients with 2019-nCoV infection who had a history of travel to Wuhan or contact with persons from Wuhan. Exposure setting included household exposure in 7 patients (70%), endemic area exposure in 2 patients (20%), and bus traveling exposure in 1 (10%) patient who had contact with 2 adult travelers from Wuhan who already had mild respiratory symptoms during the bus traveling and were confirmed with COVID after returning to Wuhan. Among 7 children exposed to household adult cases, the number of secondary symptomatic cases including the child ranged from 1 to 4 (mean: 2.43). For the 3-month-old infant (patient 7 in Table 1), her parents developed symptomatic COVID 7 days after they looked after the sick baby without protection measures. The interval between symptom onset and exposure to index symptomatic case ranged from 2 to 10 days (mean: 6.5 days), and the interval between symptom onset and departure from endemic areas was 1 day and 9 days.

Received 7 February 2020; editorial decision 21 February 2020; accepted 25 February 2020; published online February 28, 2020.

^aJ. C., J. X., and D. L. contributed equally to this paper.

Correspondence: M. Zeng, Department of Infectious Diseases, Children's Hospital of Fudan University, 399 Wanyuan Rd, Shanghai 201102, China (zengmeigao@aliyun.com).

Clinical Infectious Diseases[®] 2020;71(6):1547–51

[©] The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciaa198

Basic information 13 Jan 1 Feh Admission date 13 Jan 3 Jan 1 Feh City Shangbai Shangbai Shangbai Shangbai Shangbai Age (month) B4 13 1 13 1 108 Shangbai Age (month) B4 13 1 13 1 108 Shangbai Shang							
19 Jan25 Jan31 JanShanghaiShanghaiShanghaiShanghaiShanghaiShanghaiShanghaiShanghaiBdFemaleShanghaiShanghaiBdFemaleHouseholdFemaleMaleHouseholdHouseholdEpidemicareaSterYesYesVersonSedirectlyYesYesUnknownSymptom onset andS7UnknownSymptom onset andS71Symptom onset andYesYesSymptom onset andYesYesSymptom onset andYesYesSymptom onset andSYesSymptom onset andSYesSymptom onset andYesYesSymptom onset andYesYesSymptom onset andSYesSymptom onset andSYesSymptom onset andYes <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
Shanghai 84 Shanghai 131 Shanghai 84 Shanghai 131 Shanghai 131 MaleHouseholdHouseholdHouseholdEqualeMaleHouseholdHouseholdHouseholdEqualeHouseholdYesYesYesUnknownSymptomonset andSZUnknownSymptomonset andSZUnknownSymptomotic cases111Symptomotic cases111 <td></td> <td>3 Feb</td> <td>30 Jan</td> <td>26 Jan</td> <td>1 Feb</td> <td>27 Jan</td> <td>27 Jan</td>		3 Feb	30 Jan	26 Jan	1 Feb	27 Jan	27 Jan
84 131 131 Male Female Female Male Household Pousehold Epidemicarea Household Yes Yes Unknown Father Adult sister Unknown Symptomonset and S 7 1 Symptomonset and S 7 Unknown Symptomonset and S 7 1 S S 7 1 S Yes Yes 1 S Yes Ye	Shanghai	Shanghai	Qingdao	Haikou	Sanya	Sanya	Hefei
Male Female Female Rusehold Household Epidemicarea Rather Yes Yes Unknown Symptomonset and S 2 Unknown Symptomonset and S 7 1 Symptomonset and S 1 1 Symptomonset and Yes Yes Yes Symptomonset and Yes Yes Yes Symptomonset and Yes Yes Yes Symptomonset and<	108	7	72	03	48	96	60
Induction tendenceInduction HouseholdInduction HouseholdInduction HouseholdInduction HouseholdsedirectlyYesYesUnknown Unknownsymptomonset and ase (days)87Unknownsymptomotect cases111symptomotect cases111site38.038.4377site38.038.4377site111site111siteYesYesYesintYesYes<	Male	Female	Female	Female	Female	Male	Male
HouseholdHouseholdHouseholdEpidemic areax case directlyYesYesUnknownBen symptomatic cases11Unknownen symptomatic cases111en symptomatic cases111en symptomatic cases111en symptomatic cases111en symptomatic cases111en symptomatic cases111en symptomatic cases111cases (days)38.038.4377cases (days)38.038.4377cases38.038.4377cases38.038.4377cases111cases111casesYesYessummentYesYessount ($x 10^3/L$);16.0 f5.9count ($x 10^3/L$);15.913							
x case directlyYesYesUnknownFatherFatherAdult sisterUnknowneen symptomatic cases111ex case (days)87Unknowneen symptomatic cases111ev case (days)38.038.4377dary symptomatic cases111ido38.038.4377dary symptomatic cases111ido38.038.4377cis7YesYescisYesYesstructurdYesYesstructurdYesYessount (x10 ³ /L);16.015.9count (x10 ³ /L);16.015.9sount (x10 ³ /L);15.913		Household	Household	Epidemic area	Household	Household	Household
Father Adult sister Unknown een symptomatic cases 8 7 Unknown ex case (days) 1 1 1 dary symptomatic cases 1 1 1 dary symptomatic cases 38.0 38.4 3.77 dary symptomatic cases 38.0 38.4 3.77 cis 38.0 38.4 3.77 cis 38.0 38.4 1 cis 38.4 3.77 1 cis 38.4 3.77 1 cis 38.4 3.77 1 cis 38.4 1 1 cis 1 1 1		Yes	Yes	Unknown	Yes	Yes	Yes
en symptom onset and ex case (days)B7Unknownex case (days)1111idio idio38.038.43.77cis38.038.43.771cis38.038.43.771cis38.038.43.771cis38.038.43.771cis38.038.43.771cis38.038.43.771cis11111cis38.038.43.771cis11111cis11111cis11111cis11111cis11111cis11111cis11111cis11111cis11111cis11111cis11111cis11111cis1111cis1111cis1111cis1111cis1111cis1111cis1 </td <td>Wuhan travelers</td> <td>Grandfather</td> <td>Grandmother</td> <td>Unknown</td> <td>Friends</td> <td>Mother</td> <td>Grand- mother</td>	Wuhan travelers	Grandfather	Grandmother	Unknown	Friends	Mother	Grand- mother
dary symptomatic cases111ido $32,0$ $38,4$ $37,7$ ics $38,0$ $38,4$ $37,7$ idous)1111idous)1111idous)1111idous)1111idous)1111idous)1111idous1111 <t< td=""><td>ω</td><td>7</td><td>m</td><td>Unknown</td><td>10</td><td>2</td><td>7</td></t<>	ω	7	m	Unknown	10	2	7
cs 38.0 38.4 37.7 (days) 1 1 1 γ 58.0 38.4 37.7 (days) γ 58.0 γ 58.4 γ 53.7 γ 58.7 γ 59.7 γ 59.7 γ 59.7 γ 59.7 γ 59.7 γ 50.1 (\times 10.9/L); 16.0 1 5.9 6.7 γ 59.7 γ 59.7 γ 50.1 (\times 10.9/L); 16.0 1 5.9 γ 5.9		m	4	ი	т	ო	2
$ \begin{array}{cccccc} 1 & 1 & 1 & 1 \\ & & & & & \\ & & & & & \\ & & & &$	39.2	Afebrile	38.5	38.2	afebrile	38.6	38.5
Yes Yes Yes Yes timent Yes Yes Yes Sa Normal Normal Retrocardiac on the left count (x10 ⁹ /L); 16.01 5.9 6.7 12.8 14.2 13	1		1	-			-
Yes Yes		Yes			Yes		Yes
Yes Yes hes Yes hes Yes yes Yes		Yes					
Yes Yes itment Yes gs Yes Js Normal normal		Yes					
Yes Yes itment Yes yes Yes		Yes					
timent Yes Yes Yes Jacob Yes Yes Jacob Yes Yes Normal Normal Retrocardiac opacity on the left on the left on the left 12.8 14.2 13	Yes					Yes	
trment Yes Yes Yes Yes Js Normal Normal Retrocardiac opacity opacity count (x10 ⁹ /L); 16.0 t 5.9 6.7 12.8 14.2 13							
titment Ves Yes Yes Js Normal Normal Retrocardiac opacity on the left count (x10 ⁹ /L); 16.0 t 12.8 14.2 13							
itment Yes Yes Yes Yes Yes Yes Yes And Yes							
Normal Normal Retrocardiac opacity on the left on the		Yes	Yes	Yes	Yes	Yes	Yes
B Normal Normal Retrocardiac opacity on the left sount (×10 ⁹ /L); 16.0 f 5.9 6.7 12.8 14.2 13			Yes	Yes	Yes	Yes	Yes
Normal Normal Retrocardiac opacity on the left count (×10 ⁹ /L); 16.0 † 5.9 6.7 12.8 14.2 13							
count (×10 ⁹ /L); 16.0† 5.9 6.7 12.8 14.2 13	rdiac Opacities in the right lung sft	Opacities in the right lung	Normal	Normal	Opacities in the right lung	Normal	Normal
16.01 5.9 6.7 12.8 14.2 13							
12.8 14.2 13 nge	3.24	8.0	0.9	9.7	5.4	11.9↑	12.5↑
		11.3	13	12.3	13.1	12.1	14.4
Neutrophil count (x10 ⁹ /L); 11.2 1 3.4 3.2 1.1 4 (normal range 2.0–7.0)		2.0	1.6↓	4.2	1.3 ¢	8.07	7.4

Table 1. Epidemiological and Clinical Features Among 2019-nCoV Infected Children

-
(1)
=
Ē
=
_
ū
-
<u> </u>
ദ
_
abl

oote count (x10 ^f L), (normal range3.21.71.21.75.13.74.213.60.01count138184211312188184311311 M_1 , (normal range (s2-341)13816080016018001601800560505 M_2 , (normal range (s2-341)138160180016018000.070.030.070.020.05 M_2 , (normal range (s2-341)20111494.33112.33011132.2010.07 M_2 , (normal range (M_1 , (normal range20111492.301132.010.07 M_2 2011092.020.070.030.070.02 M_2 2011492.3112.33.01113.62.010.07 M_2 201192.25197142124.551.0128.0 M_2 2142.25197142124.551.0128.0 M_2 2142.25197142124.551.0128.0 M_2 2142.25197142124.551.0128.0 M_2 2142.25197142124.551.0128.0 M_2 2142.25197142124.551.0128.0 M_2 2142.25197142124.551.0128.0 M_2 2142.2519.1142124.551.		Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10
138 134 211 312 138 134 311 $52-311$ 501 80 1601 301 301 66 56 55 $ormalange$ 501 80 1601 301 301 56 55 55 $alrange$ 007 003 008 007 501 502 502 JU_i (normal 201 130 232 123 3301 13 202 202 JU_i (normal 310 232 102 012 202 202 JU_i (normal 310 214 212 123 3301 135 202 202 JU_i (normal 310 214 212 214 212 201 201 201 JU_i (normal 310 212 122 122 122 201 201 201 201 JU_i (normal 312 <td>Lymphocyte count (×10⁹/L); (normal range 1.2–4.0)</td> <td></td> <td>1.7</td> <td>1.2</td> <td>1.7</td> <td>5.1</td> <td>3.7</td> <td>4.2†</td> <td>3.6</td> <td>2.1</td> <td>3.3</td>	Lymphocyte count (×10 ⁹ /L); (normal range 1.2–4.0)		1.7	1.2	1.7	5.1	3.7	4.2†	3.6	2.1	3.3
ormal range 1501 80 15.01 35.01 35.01 30 5.6 0.5 al range 0.07 0.03 0.08 0.07 0.03 0.07 0.02 al range 0.07 0.03 0.08 0.07 0.12 0.03 0.02 Jult, Inormal 29.01 14.9 42.31 12.3 33.01 13 12 201 Jult, Inormal 170 7.7 19.8 26.2 1001 13.6 40.0 19.0 Jult, Inormal 33.0 14.0 25.0 1001 13.6 40.0 19.0 Jult, Inormal 33.0 14.2 24.5 51.01 28.0 10.0 Jult, Inormal 33.0 14.0 32.0 13.0 13.6 16.0 20.0 Jult, Inormal 33.0 14.1 51.0 23.0 15.0 23.0 Jult, Inormal 34.1 161 22.8 13.01 58.1 19.4 28.0 <t< td=""><td>Platelet count (×10⁹/L); (normal range 162–341)</td><td>138</td><td>184</td><td>211</td><td>312</td><td>188</td><td>186</td><td>494†</td><td>311</td><td>357↑</td><td>266</td></t<>	Platelet count (×10 ⁹ /L); (normal range 162–341)	138	184	211	312	188	186	494†	311	357↑	266
al range 0.7 0.03 0.04 0.07 0.07 0.07 0.02 ML $290t$ 149 $4.23t$ 123 $330t$ 13 12 $270t$ 0.07 0.02 ML $(normal)$ 120 214 2.52 197 $142t$ 24.5 $100t$ $120t$ $200t$ $100t$ $100t$ $120t$ <th< td=""><td>C-reactive protein (mg/L); (normal range 0.0–8.0)</td><td>15.0↑</td><td>8.0</td><td>16.0↑</td><td>35.01</td><td>8.0</td><td>7.0</td><td>5.6</td><td>0.5</td><td>3.1</td><td>4.8</td></th<>	C-reactive protein (mg/L); (normal range 0.0–8.0)	15.0↑	8.0	16.0↑	35.01	8.0	7.0	5.6	0.5	3.1	4.8
omal 29.01 14.9 $4.3.3$ 12.3 27.01 J/L ; (normal 17.0 7.7 19.8 26.2 1001 13.6 40.0 19.0 J/L ; (normal 3.0 21.4 275 19.7 142.7 24.5 51.01 28.0 $ge 28-76$) 3.7 4.1 3.2 19.7 142.7 24.5 51.01 28.0 $ge 28-76$) 3.7 4.1 3.2 19.7 142.7 24.5 58.0 19.0 $ge 28-76$) 3.7 4.1 3.2 19.4 28.0 19.0 28.0 $ge 28-76$) 3.7 4.1 3.2 19.4 28.0 10.0 19.0 $ge 28-76$) 3.7 4.1 3.2 19.4 28.0 10.0 19.0 $ge 20-65$ 394.7 161 228 159.4 28.0 10.0 10.0 $hote 065$ 0.61 10.0 19.4 28.0 10.1 23.0 10.0 <td>Procalcitonin (ng/dL);(normal range 0.0–0.5)</td> <td>0.07</td> <td>0.03</td> <td>0.08</td> <td>0.07</td> <td>0.12</td> <td>0.03</td> <td>0.07</td> <td>0.02</td> <td>0.05</td> <td>60.0</td>	Procalcitonin (ng/dL);(normal range 0.0–0.5)	0.07	0.03	0.08	0.07	0.12	0.03	0.07	0.02	0.05	60.0
J/L; (normal 120 77 19.8 26.2 1001 13.6 40.0 19.0 (U/L) ; (normal 33.0 21.4 235 19.7 142 24.5 51.01 28.0 92.8^{-7} (5) 3.7 4.1 3.2 3.2 19.1 142 28.0 19.0 92.8^{-7} (5) 3.7 4.1 3.2 3.2 19.4 28.0 19.0 92.8^{-7} (5) 3.7 4.1 3.2 3.2 1.94 28.0 10.0 10° 3.94 161 2.28 189 3.687 19.4 280 Normal 10° 3.94 161 2.28 189 3.687 19.4 280 Normal 10° 3.947 161 2.28 189 3.687 19.4 280 Normal 10° 3.947 161 2.89 16.04 2.80 Normal 10° 0.51 0.51 0.51 19.4	Creatine kinase-MB (U/L);(normal range <25)	29.0†	14.9	42.3 †	12.3	33.0†	13	12	27.0†	31.0 †	19
(U/L) (1.4) (2.14) (2.5) (1.4) (2.4) (2.14) (2.8) $ge 2.8^{-7}(6)$ (3.7) (4.1) (3.2) (3.2) (3.1) (4.1) (2.9) (6.1) (2.6) $range 21-65$) (2.9) (5.4) (4.0) (3.0) (5.4) (4.0) (3.0) (5.4) (2.9) (6.1) (2.6) $L)$ (2.9) (5.4) (4.8) (3.9) (3.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (6.1) (2.9) (0.1) <td>Alanine aminotransferase (U/L); (normal range 9.0-50.0)</td> <td>17.0</td> <td>7.7</td> <td>19.8</td> <td>26.2</td> <td>100↑</td> <td>13.6</td> <td>40.0</td> <td>19.0</td> <td>18.0</td> <td>14.0</td>	Alanine aminotransferase (U/L); (normal range 9.0-50.0)	17.0	7.7	19.8	26.2	100↑	13.6	40.0	19.0	18.0	14.0
$92 \cdot 3 \cdot 7$ $4 \cdot 1$ $3 \cdot 2$ $3 \cdot 2$ $1 \cdot 3 \cdot 1$ $3 \cdot 2$ $3 \cdot 1$ $3 \cdot 1$ $4 \cdot 1$ $2 \cdot 6 \cdot 1$ $2 \cdot 1 \cdot 1$ $2 \cdot 6 \cdot 1$ $2 \cdot 1 \cdot 1$	Aspartate aminotransferase (U/L); (normal range 15-0-40-0)	33.0	21.4	27.5	19.7	142↑	24.5	51.0 t	28.0	20.0	34.0
	Urea (mmol/L); (normal range 2·8–7.6)	3.7	4.1	3.2	3.2	1.9↓	3.8	0.5 ↓	2.6↓	3.0	3.0
L): 3941 161 228 189 3681 194 280 Normalnge 0.0-0.5) 0.61 0.3 0.61 0.2 Normal 0.2 NormalabsPositivePositivePositivePositivePositivePositivePositiveabsPositivePositivePositivePositivePositivePositivePositivein respiratory12 22 88615812PositiveNegativePositivePositivePositivePositiveNot testedNot testedIn stool (day)>3010>20>19>18Not testedNot testedNot testedNogativeNegativeNegativeNegativeNot testedNot testedNot testedNot testedNotativeNegativeNegativeNegativeNot testedNot testedNot testedNot testedNotativeNegativeNegativeNot testedNot testedNot testedNot testedNotativeNegativeNotativeNot testedNot testedNot testedNot testedNotativeNotativeNotativeNot testedNot testedNot tested	Creatinine (µmol/L);(normal range 21–65)	29.0	54.0	54.0	48.0	13.0↓	58.9	16.0↓	23.0	38.0	33.0
Inge 0.0-0.5) 0.61 0.2 NormalabsPositivePositivePositivePositivePositiveabsPositivePositivePositivePositivePositivein respiratory122288615812PositiveNegativePositivePositivePositivePositiveNot testedNot testedNot testedIn stool (days)>3010>20>19>18Not testedNot testedNot testedNot testedNegativeNegativeNegativeNegativeNot testedNot testedNot testedNot testedNot testedNotativeNegativeNegativeNegativeNot testedNot testedNot testedNot testedNotativeNegativeNegativeNegativeNot testedNot testedNot testedNotativeNegativeNegativeNegativeNot testedNot testedNot tested	Lactate dehydrogenase (U/L); (normal range 110–290)	394↑	161	228	189	368↑	194	280	Normal	Normal	304↑
abs Positive Positive Positive Positive Positive Positive In respiratory 12 22 8 8 6 15 8 12 Positive Negative Not isol 0 20 519 518 Not tested ⁶ Not tested ⁶ In stool (days) >30 10 >20 519 518 Not tested ⁶ Not tested ⁶ Nogative Negative Negative Negative Negative Not tested ⁶ Not tested ⁶ Nooative Negative Negative Negative Not tested ⁶ Not tested ⁶ Not tested ⁶ Nooative Negative Negative Not tested ⁶ Not tested ⁶ Not tested ⁶	D-dimer (µg/mL); (normal range 0.0-0.5)	0.6↑		0.3	0.6↑		0.2	Normal			
oharyngeal/ throat swabsPositivePositivePositivePositivePositivePositiveon of virus shedding in respiratory122288615812bs (days)PositiveNot set of the set o	Detection of 2019-nCoV RNA										
on of virus shedding in respiratory 12 22 8 8 6 15 8 12 bs (days) the solution of virus shedding in stool (days) >30 10 >20 >19 >19 >18 Not tested [®] Positive Not tested [®] >23 Not tested [®] on the solution of virus shedding in stool (days) >30 10 >20 >19 >19 >18 Not tested [®] >23 Not tested [®] >10 Not tested [®] >23 Not tested [®] >10 Not tested [®] Not	Nasopharyngeal/ throat swabs	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive	Positive
Positive Nositive Positive Positive Not tested ^e <	Duration of virus shedding in respiratory swabs (days)	12	22	ω	ω	9	15	ω	12	14	15
ion of virus shedding in stool (days) >30 10 >20 >19 >19 >18 Not tested ^e >23 Not tested ^e Negative Negative Negative Negative Negative Not tested ^e Negative Not tested ^e Negative Not tested ^e Negative Negative Negative Negative Negative Not tested ^e Negative Not tested ^e Negative Not tested ^e	Stool	Positive	Negative	Positive	Positive	Positive	Not tested ^c	Positive	Not tested ^c	Not tested ^c	Not tested ^c
Negative Negative Negative Negative Negative Not tested ^e	Duration of virus shedding in stool (days)	>30	10	>20	>19	>18	Not tested ^c	>23	Not tested ^c	Not tested ^c	Not tested ^c
Negative Negative Negative Negative Negative Not tested ^e Negative Not tested ^e	Urine	Negative	Negative	Negative	Negative	Negative	Not tested ^c	Negative	Not tested ^c	Not tested ^c	Not tested ^o
	Serum	Negative	Negative	Negative	Negative	Negative	Not tested ^c	Negative	Not tested ^c	Not tested ^c	Not tested ^c

eloped symptor deve expo ^oThe number of symptomatic secondary cases included the sum of the affect ^oNot tested means the patient's sample not being tested for 2019-nCoV RNA.

The 10 patients were aged 3–131 months (mean: 74 months), and the ratio of male to female was 1:1.5. Eight (80%) patients had fever, 6 (60%) had cough, 4 (40%) had sore throat, 3 (30%) had stuffy nose, and 2 (20%) had sneezing and rhinorrhea. None of patients had diarrhea or dyspnea during the course of illness. Fever resolved 24 hours after fever onset with the peak of fever ranging from 37.7°C to 39.2°C. Chest radiograph revealed unilateral patchy infiltrate in 4 (40%) of 10 patients. The laboratory findings showed (median): white blood cell count 7.35×10^9 /L, C-reactive protein 7.5 mg/L, procalcitonin 0.07 ng/dL, creatine kinase-MB 23 U/L, alanine aminotransferase 18.5 U/L, aspartate aminotransferase 27.7 U/L, urea 3.1 mmol/L, creatinine 35.5 µmol/L, lactate dehydrogenase 25 U/L, and D-dimer 0.45 µg/mL; influenza virus A and B were all negative. All patients received symptomatic treatment with no need of oxygen therapy, and a few of the patients with pneumonia received empirical antibiotic therapy. As of 19 February, all patients had been discharged when they recovered uneventfully with 2 consecutive respiratory samples tested negative for 2019-nCoV RNA.

2019-nCoV RNA was detected in nasopharyngeal and throat swabs from all patients within 4–48 hours after symptom onset. 2019-nCoV RNA in nasopharyngeal/throat swabs was undetectable within 6–22 days (mean: 12 days) after illness onset. Six patients had fecal samples tested for 2019-nCoV RNA within 3–13 days after illness onset, and 5 (83.3%) showed positivity (of note, fecal sample from patient 2 was obtained on day 10 after illness onset and showed negativity). As of 19 February, these 5 patients still have 2019-nCoV RNA detected in feces within 18–30 days after illness onset and are under close follow-up. Five patients had urine and serum samples tested for 2019-nCoV RNA within 2–3 days after illness onset, and all showed negativity.

DISCUSSION

This is the first case series report on 2019-nCoV infection in children. Our preliminary clinical findings showed that children with COVID usually presented with mild respiratory infections, as compared with adult cases [9]. For pediatric patients, fever and mild cough are common symptoms at disease onset. For mild cases, fever is brief and resolved rapidly. A few of the patients presenting with/without cough also showed radiographic evidence of patchy infiltrate at symptom onset. In one study of a family cluster, an asymptomatic 10-year-old child infected with 2019-nCoV due to household exposure had radiological ground-glass lung opacities [7]. Radiographic evidence of pneumonia was a characteristics of 2019-nCoV infection at the earliest stage of infection; thus, close observation is very necessary for a child with either mild symptomatic or asymptomatic infection. We d not recommend use of antiviral agents for the treatment of self-limited nonsevere COVID because no evidence has shown the effectiveness of antiviral agents currently available. Influenza virus screening is necessary to rule out the possible coinfection considering the seasonal overlap between influenza and COVID. Empirical antibiotic initiation is not recommended for treatment of nonsevere 2019-nCoVassociated pneumonia without evidence of superbacterial infection. By 22 January 2020, all notifiable COVID cases and severe cases were aged \geq 15 years old in Wuhan [9, 10]. In theory, children are also susceptible to 2019-nCoV and mild or atypical cases were largely underdiagnosed according to the initial screening criteria, which focused on suspected pneumonia cases [2].

The epidemiological evidence has demonstrated that COVID can be transmitted from person to person, and the basic reproductive number was estimated to be 2.2 [10]. We observed the mean number of secondary symptomatic cases in household exposure settings was 2.43. Our findings highly support the evidence of human-to-human transmission of COVID. All pediatric patients had an epidemiological link directly or indirectly to Wuhan or other endemic area of Hubei, where the outbreak of COVID originated and is ongoing. Most of the pediatric cases occurring outside of Wuhan were secondary cases after exposure to adult cases through household contact or travel contact. However, we cannot neglect the potential risk of transmission from the infected child to adult contacts, as shown in patient 7. Thus, personal medical protection is crucial when care providers look after the infected child. The major pattern of transmission was intrafamily transmission. The general transmission pattern of COVID is similar to that of SARS and MERS in children [11, 12]. Based on our field investigation, the mean incubation period between household exposure to a symptomatic adult case and symptom onset was 6.5 days, longer than 5.4 days observed in adult cases [10]. This difference could be suggestive of longer incubation period for 2019-nCoV infection in children. Currently, these epidemiological features are a key clue to help early recognition of 2019-nCoV infection in children outside of Wuhan and take infection prevention control interventions in time.

Virus shedding in respiratory specimens is longer in children with mild COVID, which will impose a challenge for infection control. 2019-nCoV RNA was not detected in serum samples in our study. Viremia could be related to the severity of disease because 2019-nCoV RNA was detected in blood samples obtained from 15% of adult patients with pneumonia [9]. Surprisingly, we also noted a high frequency (83.3%) of 2019-nCoV RNA detection in feces in mild patients and prolonged virus RNA shedding in feces for at least 2 weeks and even more than 1 month, which raises a question concerning whether the gastrointestinal tract may be another site of viral replication. The impact on 2019-nCoV shedding in feces on transmission model and infection prevention and control should be further assessed. The COVID epidemic is now spreading globally. Further research and surveillance are crucial to help us understand the clinical characteristics and natural history of 2019-nCoV infection in children.

Notes

Financial support. This study was supported by the grant from the National Science and Technology Major Project of China during the "13th Five-Year" Plan Period (grant 2017ZX10103009–007).

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

- World Health Organization. WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. Available at: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhanchina. Accessed 11 January 2020.
- National Health Commission of The People's Republic of China. Interim protocol
 of diagnosis and treatment of 2019 novel coronavirus-associated pneumonia (the
 second version). Available at: http://www.nhc.gov.cn/jkj/s3577/202001/c67cfe29e
 cf1470e8c7fc47d3b751e88.shtml. Accessed 18 January 2020.
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–33.

- 4. World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Available at: https://www.who.int/news-room/ detail/30-01-2020-statement-on-the-second-meeting-of-the-internationalhealth-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-nCov). Accessed 31 January 2020.
- Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41:145–51.
- World Health Organization. Novel Coronavirus(2019-nCoV) Situation Report-22. Available at: https://www.who.int/docs/default-source/coronaviruse/ situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2. Accessed 11 February 2020.
- Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395:514–23.
- Cai JH, Wang XS, Ge YL, et al. The first case report of 2019 novel coronavirus infection in children in Shanghai. Zhong Hua Er Ke Za Zhi 2020; 58:E002.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
- Li Q, Guan X, Wu P, Wang X, Zhou L. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 2020-01-29.
- 11. Stockman LJ, Massoudi MS, Helfand R, et al. Severe acute respiratory syndrome in children. Pediatr Infect Dis J 2007; 26:68–74.
- Thabet F, Chehab M, Bafaqih H, Al MS. Middle East respiratory syndrome coronavirus in children. Saudi Med J 2015; 36:484–6.